The WHO 2016 guidelines for classification of tumours of the central nervous system integrates molecular genomic information with histological analysis. The central nervous system tumour service offers a range of tests for the differential diagnosis of CNS tumours, provides prognostic information, and may aid in treatment decisions or clinical trial recruitment.
We require a minimum 4x5µM thick unstained sections from a pathology specimen, either slide mounted or as scrolls (scrolls are required for KIAA1549-BRAF fusion testing), which must have been reviewed by a histopathologist and be accompanied by a completed test request form, clearly stating the proportion of neoplastic cells in the block. For optimum detection of somatic mutations >20% neoplastic cell content is required (>30% for TERT promoter mutation testing). Referrals will be accepted from oncologists and pathologists. If MGMT hypermethylation or KIAA1549-BRAF fusion testing is requested in addition to another test, we require an additional 4x5µM sections.
Price & reporting times
|Test||Technique||Price (£ ex VAT)||TRT|
|hTERT promoter mutations||Sanger sequencing||POA||14cd|
|MGMT promoter hypermethylation||Pyrosequencing||POA||14cd|
|BRAF codon 600 mutations||Pyrosequencing/COBAS||POA||14cd|
|KIAA1549:BRAF fusion||Droplet Digital PCR||POA||14cd|
|C11orf95-RELA fusion||Droplet Digital PCR||POA||14cd|
|EGFRvIII Transcript||Droplet Digital PCR||POA||14cd|
|Meningioma/schwannoma panel||Next generation sequencing panel||POA||14cd|
|NGS Somatic cancer/ Glioma sub-panel||Next generation sequencing panel||POA||14cd|
Test validation & quality assurance - information for users
Please see our referral guidelines for more information.